Tina Nova has joined the board of directors of Heska, a veterinary diagnostic products manufacturer, the company said last week. Nova is president, CEO, director, and co-founder of Genoptix. She served as president and COO of Nanogen from 1994 to 2000. Nova holds a PhD in biochemistry from the University of California, Riverside and a BSc in biological sciences from the University of California, Irvine.
Michael Treble has become CEO of the Ibis program of Isis Pharmaceuticals, the company said yesterday. Ibis plans to develop a biosensor to identify infectious organisms. Prior to joining Isis, he founded Tienta Sciences and SonoPlot. Before that, he was president and CEO of NimbleGen Systems. He was also executive vice president, COO, and director of Third Wave Technologies. Treble holds an MBA from the University of Buffalo and a BS from Canisius College, also in Buffalo.
In addition, Richard DiMarchi has joined the board of directors of Isis, the company said last month. He is a professor of biomolecular science at Indiana University, Bloomington. Prior to this, he led the biotechnology group at Eli Lilly Research Laboratories. He is also a partner at Twilight Venture Fund, and is a former member of the board of the Biotechnology Industry Organization. DiMarchi holds a PhD from Indiana University, and a BS from Florida Atlantic University.
Deborah Smeltzer has become CFO and vice president for operations of Dynavax, the Berkeley, Calif.-based company said today. She joins Dynavax from Applied Biosystems, where she was vice president and general manager of the company’s genetic analysis business. Prior to that, she was CFO and vice president of Genset, a French genomics company. Smeltzer holds an MBA from the Stanford University Graduate School of Business and an MS in medical microbiology from the University of California, Irvine.
Merrilyn Datta has become the new director of RNAi in the functional genomics business segment of Invitrogen, according to Pharmacogenomics Reporter’s sister publication, GenomeWeb News. She replaces Nikki Zahl, who has become director of genomics at Invitrogen. She was previously marketing manager for RNAi at the company. Datta holds a PhD from Harvard University.